Statement: 2 patients in the primary trial suffer from DVT, 0 in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 8/28 (28.57%)   Neutropenia 3/28 (10.71%)   Hepatitis acute 1/28 (3.57%)   Pneumonia 1/28 (3.57%)   Septic shock 1/28 (3.57%)   Femur fracture 1/28 (3.57%)   Infected neoplasm 1/28 (3.57%)   Deep vein thrombosis 1/28 (3.57%)
Secondary_evidence: Adverse Events 1:   Total: 1/24 (4.17%)   Pericardial effusion *1/24 (4.17%)   Other cardiac disorder *0/24 (0.00%)   Ejection fraction decrease *0/24 (0.00%)   Hypertension *0/24 (0.00%)   Salivary gland infection *0/24 (0.00%)   Pleural effusion *0/24 (0.00%) Adverse Events 2:   Total: 6/30 (20.00%)   Pericardial effusion *1/30 (3.33%)   Other cardiac disorder *1/30 (3.33%)   Ejection fraction decrease *1/30 (3.33%)   Hypertension *1/30 (3.33%)   Salivary gland infection *1/30 (3.33%)   Pleural effusion *2/30 (6.67%)